Fintel reports that on October 30, 2025, Citigroup maintained coverage of Bio-Rad Laboratories (NYSE:BIO.B) with a Buy recommendation. Analyst Price Forecast Suggests 21.85% Upside As of April 2, 2025 ...
Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...
The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...
The TC20 automated cell counter counts mammalian cells in one simple step using its innovative auto-focus technology and sophisticated cell counting algorithm to produce accurate cell counts in less ...
About 60% women in Europe enrolled in a national breast cancer screening programme who have a screening mammogram can feel reasonably confident that radiologists will be able to diagnose early-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback